Generic placeholder image

Current Neuropharmacology

Author(s): Flaminia Pantano, Silvia Graziano, Roberta Pacifici, Francesco Paolo Busardò and Simona Pichini*

DOI: 10.2174/1570159X1709190729101751

DownloadDownload PDF Flyer Cite As
New Psychoactive Substances: A Matter of Time

Page: [818 - 822] Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

In the last few years, a wide range of new psychoactive substances (NPS) have been produced and marketed to elude the controlled substance lists. These molecules enter the traditional illegal and web market with poor knowledge about their toxicity, mechanism of action, metabolism, abuse potential so that they are directly tested by the consumers. This perspective highlights the main issues connected with NPS: the celerity they enter and leave the market once included in the banning laws to be substituted by new legal analogues; the unavailability of analytical screening tests and certified standards to perform toxicological analyses; the time lag between NPS identification and inclusion in the controlled substances lists. Finally, the authors take a snapshot of the commitment of the Italian Early Warning System in highlighting the recent seizures of NPS as well as the distribution of NPS related intoxication and deaths as an example of what is happening in the European countries and internationally.

Keywords: NPS, analog, toxicity, early warning system, controlled substances, toxicological analysis.

[1]
Pichini, S.; Busardo, F.P.; Pacifici, R.; Kintz, P. New psychoactive substances (NPS). A new global issue: neuropharmacological, chemical and toxicological aspects. Curr. Neuropharmacol., 2017, 15(5), 656-657.
[http://dx.doi.org/10.2174/1570159X14666161220154550] [PMID: 28000553]
[2]
Richter, L.H.J.; Herrmann, J.; Andreas, A.; Park, Y.M.; Wagmann, L.; Flockerzi, V.; Müller, R.; Meyer, M.R. Tools for studying the metabolism of new psychoactive substances for toxicological screening purposes - A comparative study using pooled human liver S9, HepaRG cells, and zebrafish larvae. Toxicol. Lett., 2019, 305, 73-80.
[http://dx.doi.org/10.1016/j.toxlet.2019.01.010] [PMID: 30682400]
[3]
Peters, F.T.; Meyer, M.R. In vitro approaches to studying the metabolism of new psychoactive compounds. Drug Test. Anal., 2011, 3(7-8), 483-495.
[http://dx.doi.org/10.1002/dta.295] [PMID: 21671427]
[4]
Pichini, S.; Pacifici, R.; Marinelli, E.; Busardò, F.P. European drug users at risk from illicit fentanyls mix. Front. Pharmacol., 2017, 8, 785.
[http://dx.doi.org/10.3389/fphar.2017.00785] [PMID: 29163170]
[5]
Pichini, S.; Solimini, R.; Berretta, P.; Pacifici, R.; Busardò, F.P. Acute intoxications and fatalities from illicit fentanyl and analogues: an update. Ther. Drug Monit., 2018, 40(1), 38-51.
[PMID: 29120973]
[6]
Tittarelli, R.; Mannocchi, G.; Pantano, F.; Romolo, F.S. Recreational use, analysis and toxicity of tryptamines. Curr. Neuropharmacol., 2015, 13(1), 26-46.
[http://dx.doi.org/10.2174/1570159X13666141210222409] [PMID: 26074742]
[7]
Barceló, B.; Pichini, S.; López-Corominas, V.; Gomila, I.; Yates, C.; Busardò, F.P.; Pellegrini, M. Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: A case series. Forensic Sci. Int., 2017, 273, e10-e14.
[http://dx.doi.org/10.1016/j.forsciint.2017.01.020] [PMID: 28190538]
[8]
Solimini, R.; Pichini, S.; Pacifici, R.; Busardò, F.P.; Giorgetti, R. Pharmacotoxicology of non-fentanyl derived new synthetic opioids. Front. Pharmacol., 2018, 9, 654.
[http://dx.doi.org/10.3389/fphar.2018.00654] [PMID: 29973882]
[9]
Zaami, S.; Giorgetti, R.; Pichini, S.; Pantano, F.; Marinelli, E.; Busardò, F.P. Synthetic cathinones related fatalities: an update. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(1), 268-274.
[PMID: 29364498]
[10]
Pantano, F.; Tittarelli, R.; Mannocchi, G.; Pacifici, R.; di Luca, A.; Busardò, F.P.; Marinelli, E. Neurotoxicity induced by mephedrone: An up-to-date review. Curr. Neuropharmacol., 2017, 15(5), 738-749.
[http://dx.doi.org/10.2174/1570159X14666161130130718] [PMID: 27908258]
[11]
Busardò, F.P.; Kyriakou, C.; Napoletano, S.; Marinelli, E.; Zaami, S. Mephedrone related fatalities: a review. Eur. Rev. Med. Pharmacol. Sci., 2015, 19(19), 3777-3790.
[PMID: 26502870]
[12]
Baumann, M.H.; Walters, H.M.; Niello, M.; Sitte, H.H. Neuropharmacology of synthetic cathinones. Handb. Exp. Pharmacol., 2018, 252, 113-142.
[http://dx.doi.org/10.1007/164_2018_178] [PMID: 30406443]
[13]
Angoa-Pérez, M.; Anneken, J.H.; Kuhn, D.M. Neurotoxicology of synthetic cathinone analogs. Curr. Top. Behav. Neurosci., 2017, 32, 209-230.
[http://dx.doi.org/10.1007/7854_2016_21] [PMID: 27753008]
[14]
Details for Phenethylamines. https://www.unodc.org/LSS/SubstanceGroup/Details/275dd468-75a3-4609-9e96-cc5a2f0da467
[15]
Fantegrossi, W.E.; Murnane, K.S; Reissig, C.J. The behavioral pharmacology of hallucinogens. Biochem. Pharmacol., 2008, 75(1), 17-33.
[http://dx.doi.org/10.1016/j.bcp.2007.07.018] [PMID: 17977517]
[16]
Details for Piperazines. https://www.unodc.org/LSS/SubstanceGroup/Details/8242b801-355c-4454-9fdc-ba4b7e7689d5
[17]
Rosenbaum, C.D.; Carreiro, S.P.; Babu, K.M. Here today, gone tomorrow and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J. Med. Toxicol., 2012, 8(1), 15-32.
[http://dx.doi.org/10.1007/s13181-011-0202-2] [PMID: 22271566]
[18]
Miliano, C.; Serpelloni, G.; Rimondo, C.; Mereu, M.; Marti, M.; De Luca, M.A. Neuropharmacology of new psychoactive substances (NPS): Focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front. Neurosci., 2016, 10, 153.
[http://dx.doi.org/10.3389/fnins.2016.00153] [PMID: 27147945]
[19]
Hondebrink, L.; Zwartsen, A.; Westerink, R.H.S. Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data? Pharmacol. Ther., 2018, 182, 193-224.
[http://dx.doi.org/10.1016/j.pharmthera.2017.10.022] [PMID: 29097307]
[20]
Barceló, B.; Gomila, I.; Rotolo, M.C.; Marchei, E.; Kyriakou, C.; Pichini, S.; Roset, C.; Elorza, M.Á.; Busardò, F.P. Intoxication caused by new psychostimulants: analytical methods to disclose acute and chronic use of benzofurans and ethylphenidate. Int. J. Legal Med., 2017, 131(6), 1543-1553.
[http://dx.doi.org/10.1007/s00414-017-1648-9] [PMID: 28710651]
[21]
Graziano, S.; Anzillotti, L.; Mannocchi, G.; Pichini, S.; Busardò, F.P. Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices. J. Pharm. Biomed. Anal., 2019, 163, 170-179.
[http://dx.doi.org/10.1016/j.jpba.2018.10.011] [PMID: 30316062]
[22]
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). available at http://www.emcdda.europa.eu/emcdda-home-page_en
[23]
National relation on drug and drug addition to the Parliament available at: http://www.politicheantidroga.gov.it/it/comunicazione/notizie/relazione-annuale-al-parlamento-sul-fenomeno-delle-tossicodipendenze-in-italia-anno-2018-dati-2017/
[24]
Presidential Decree 309/90 available at https://www.altalex.com/documents/codici-altalex/2014/06/04/testo-unico-sulla-droga-ed-aprile-2014
[25]
Casati, S.; Minoli, M.; Angeli, I.; Ravelli, A.; Crudele, G.D.L.; Orioli, M. An ocfentanil-related death case: UHPLC-MS/MS analysis of the drug. Drug Test. Anal., 2019, 11(1), 173-177.
[http://dx.doi.org/10.1002/dta.2473] [PMID: 30091284]
[26]
Gerace, E.; Salomone, A.; Luciano, C.; Di Corcia, D.; Vincenti, M. First case in Italy of fatal intoxication involving the new opioid U-47700. Front. Pharmacol., 2018, 9, 747.
[http://dx.doi.org/10.3389/fphar.2018.00747] [PMID: 30042684]